Patient Experience Data May Require Separate Label, Genentech Suggests

US labeling for Genentech's Rituxan Hycela appears to have broken new ground with a 'Patient Experience' section describing summary data from a patient preference study; however, the company's global head of outcomes research says large volumes of patient-centric data would be difficult to reflect within the current labeling framework.

Data Collection - Three Arrows Hit in Red Target

More from US FDA

More from Agency Leadership